ANTIBODIES AND FV FRAGMENT RECOGNIZING ANTIGEN IOR C2
The invention relates to recombinant antibodies from monoclonal antibody IOR C5 that recognizes antigen IOR C2 of colorectal cells. Said recombinant antibodies have a reduced immunogenicity due to punctual mutations in the FRs. Said antibodies are useful for the diagnosis and therapy of colorectal t...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; spa |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | DUENAS PORTO, MARTA BELL GARCIA, HANSSEL MATEO DE ACOSTA DEL RIO, CRISTINA MARIA GAVILONDO COWLEY, JORGE VICTOR MORALES MORALES, ALEJO AYALA AVILA, MARTA IZNAGA ESCOBAR, NORMANDO RAMOS ZUZARTE, MAYRA RENGIFO CALZADO, ENRIQUE ROQUE NAVARRO, LOURDES TATIANA PEREZ RODRIGUEZ, ROLANDO |
| description | The invention relates to recombinant antibodies from monoclonal antibody IOR C5 that recognizes antigen IOR C2 of colorectal cells. Said recombinant antibodies have a reduced immunogenicity due to punctual mutations in the FRs. Said antibodies are useful for the diagnosis and therapy of colorectal tumors, their metastasis and relapses.
The invention relates to the obtention of novel recombinant antibodies of novel recombinant antibodies from murine antibody ior C5 produced by the hybridome deposited under number ECCC 97061101 in accordance with the Budapest Treaty. Said recombinant antibodies were obtained using recombinant DNA technology and are characterized in that they recognize antigen ior C2. The recombinant antibodies are specifically chimeric antibody, humanized antibody and the single-chain Fv fragment. The chimeric antibody contains variable domains of murine immunoglobuline and the constant regions of human immunoglobuline. The humanized antibody contains the constant regions of human immunoglobuline and has been specifically modified in the murine framework regions (FRs) and within the latter, in those areas that may result in an antigenic site for cells T. The Fv fragment contains the variable domains of murine immunoglobuline. The invention also relates to the utilization of recombinant antibodies derived from murine antibody ior C5 in the diagnosis and therapy of colorectal tumors, the metastasis thereof and recurrences.
La presente invención se relaciona con la obtención de nuevos anticuerpos recombinantes a partir del anticuerpo murino ior C5 producido por el hibridoma depositado según el tratado de Budapest bajo el número ECCC 97061101. Dichos anticuerpos recombinantes se obtuvieron mediante el empleo de la tecnología del ADN recombinante, y están caracterizados por su reconocimiento al antígeno denominado ior C2. Los anticuerpos recombinantes son específicamente, el anticuerpo quimérico, el anticuerpo humanizado y el fragmento tipo Fv de cadena sencilla. El anticuerpo quimérico contiene los dominios variables de la inmunoglobulina murina y las regiones constante de la inmunoglobulina humana. El anticuerpo humanizado contiene las regiones constante de la inmunoglobulina humana y ha sido modificado específicamente en la región de los marcos (FRs) murinos y dentro de estos en aquellas zonas que pudieran resultar en un sitio antigénico par las células T. El fragmento Fv contiene los dominios variables de la inmunoglobulina murina. La present |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO0136485A2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO0136485A2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO0136485A23</originalsourceid><addsrcrecordid>eNrjZDB19AvxdPJ38XQNVnD0c1FwC1NwC3J093X1C1EIcnX2d_fzjPL0c1cAKXN39VPw9A9ScDbiYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXx4f4GhsZmJhamjkbGRCgBAIBEJwc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ANTIBODIES AND FV FRAGMENT RECOGNIZING ANTIGEN IOR C2</title><source>esp@cenet</source><creator>DUENAS PORTO, MARTA ; BELL GARCIA, HANSSEL ; MATEO DE ACOSTA DEL RIO, CRISTINA MARIA ; GAVILONDO COWLEY, JORGE VICTOR ; MORALES MORALES, ALEJO ; AYALA AVILA, MARTA ; IZNAGA ESCOBAR, NORMANDO ; RAMOS ZUZARTE, MAYRA ; RENGIFO CALZADO, ENRIQUE ; ROQUE NAVARRO, LOURDES TATIANA ; PEREZ RODRIGUEZ, ROLANDO</creator><creatorcontrib>DUENAS PORTO, MARTA ; BELL GARCIA, HANSSEL ; MATEO DE ACOSTA DEL RIO, CRISTINA MARIA ; GAVILONDO COWLEY, JORGE VICTOR ; MORALES MORALES, ALEJO ; AYALA AVILA, MARTA ; IZNAGA ESCOBAR, NORMANDO ; RAMOS ZUZARTE, MAYRA ; RENGIFO CALZADO, ENRIQUE ; ROQUE NAVARRO, LOURDES TATIANA ; PEREZ RODRIGUEZ, ROLANDO</creatorcontrib><description>The invention relates to recombinant antibodies from monoclonal antibody IOR C5 that recognizes antigen IOR C2 of colorectal cells. Said recombinant antibodies have a reduced immunogenicity due to punctual mutations in the FRs. Said antibodies are useful for the diagnosis and therapy of colorectal tumors, their metastasis and relapses.
The invention relates to the obtention of novel recombinant antibodies of novel recombinant antibodies from murine antibody ior C5 produced by the hybridome deposited under number ECCC 97061101 in accordance with the Budapest Treaty. Said recombinant antibodies were obtained using recombinant DNA technology and are characterized in that they recognize antigen ior C2. The recombinant antibodies are specifically chimeric antibody, humanized antibody and the single-chain Fv fragment. The chimeric antibody contains variable domains of murine immunoglobuline and the constant regions of human immunoglobuline. The humanized antibody contains the constant regions of human immunoglobuline and has been specifically modified in the murine framework regions (FRs) and within the latter, in those areas that may result in an antigenic site for cells T. The Fv fragment contains the variable domains of murine immunoglobuline. The invention also relates to the utilization of recombinant antibodies derived from murine antibody ior C5 in the diagnosis and therapy of colorectal tumors, the metastasis thereof and recurrences.
La presente invención se relaciona con la obtención de nuevos anticuerpos recombinantes a partir del anticuerpo murino ior C5 producido por el hibridoma depositado según el tratado de Budapest bajo el número ECCC 97061101. Dichos anticuerpos recombinantes se obtuvieron mediante el empleo de la tecnología del ADN recombinante, y están caracterizados por su reconocimiento al antígeno denominado ior C2. Los anticuerpos recombinantes son específicamente, el anticuerpo quimérico, el anticuerpo humanizado y el fragmento tipo Fv de cadena sencilla. El anticuerpo quimérico contiene los dominios variables de la inmunoglobulina murina y las regiones constante de la inmunoglobulina humana. El anticuerpo humanizado contiene las regiones constante de la inmunoglobulina humana y ha sido modificado específicamente en la región de los marcos (FRs) murinos y dentro de estos en aquellas zonas que pudieran resultar en un sitio antigénico par las células T. El fragmento Fv contiene los dominios variables de la inmunoglobulina murina. La presente invención además se relaciona con el uso de los anticuerpos recombinantes derivados del anticuerpo murino ior C5 para el diagnóstico y terapia de tumores colorrectales, sus metástasis y recidivas.
La présente invention concerne l'obtention de nouveaux anticorps recombinants à partir de l'anticorps murin ior C5 produit par l'hybridome qui a fait l'objet du dépôt numéro ECCC 97061101 selon le traité de Budapest. Lesdits anticorps recombinants, que l'on a obtenus par utilisation de la technologie de l'ADN recombiné, sont caractérisés en ce qu'ils reconnaissent l'antigène appelé ior C2. Ces anticorps recombinants sont notamment l'anticorps chimère, l'anticorps humanisé et le fragment du type Fv à chaîne simple. L'anticorps chimère contient les domaines variables de l'immunoglobuline murine et les régions constantes de l'immunoglobuline humaine. L'anticorps humanisé, qui contient les régions constantes de l'immunoglobuline humaine, a été modifié spécifiquement au niveau des régions charpente (framework regions) murines, et à l'intérieur de celles-ci, dans les zones susceptibles de donner lieu à un site antigénique pour les lymphocytes T. Le fragment Fv contient les domaines variables de l'immunoglobuline murine. La présente invention concerne également l'utilisation des anticorps recombinants dérivés de l'anticorps murin ior C5 pour le diagnostic et le traitement des tumeurs colorectales, de leurs métastases et de leurs récidives.</description><edition>7</edition><language>eng ; fre ; spa</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE ; HUMAN NECESSITIES ; HYGIENE ; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PHYSICS ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPIRITS ; TESTING ; VINEGAR ; WINE</subject><creationdate>2001</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20010525&DB=EPODOC&CC=WO&NR=0136485A2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20010525&DB=EPODOC&CC=WO&NR=0136485A2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>DUENAS PORTO, MARTA</creatorcontrib><creatorcontrib>BELL GARCIA, HANSSEL</creatorcontrib><creatorcontrib>MATEO DE ACOSTA DEL RIO, CRISTINA MARIA</creatorcontrib><creatorcontrib>GAVILONDO COWLEY, JORGE VICTOR</creatorcontrib><creatorcontrib>MORALES MORALES, ALEJO</creatorcontrib><creatorcontrib>AYALA AVILA, MARTA</creatorcontrib><creatorcontrib>IZNAGA ESCOBAR, NORMANDO</creatorcontrib><creatorcontrib>RAMOS ZUZARTE, MAYRA</creatorcontrib><creatorcontrib>RENGIFO CALZADO, ENRIQUE</creatorcontrib><creatorcontrib>ROQUE NAVARRO, LOURDES TATIANA</creatorcontrib><creatorcontrib>PEREZ RODRIGUEZ, ROLANDO</creatorcontrib><title>ANTIBODIES AND FV FRAGMENT RECOGNIZING ANTIGEN IOR C2</title><description>The invention relates to recombinant antibodies from monoclonal antibody IOR C5 that recognizes antigen IOR C2 of colorectal cells. Said recombinant antibodies have a reduced immunogenicity due to punctual mutations in the FRs. Said antibodies are useful for the diagnosis and therapy of colorectal tumors, their metastasis and relapses.
The invention relates to the obtention of novel recombinant antibodies of novel recombinant antibodies from murine antibody ior C5 produced by the hybridome deposited under number ECCC 97061101 in accordance with the Budapest Treaty. Said recombinant antibodies were obtained using recombinant DNA technology and are characterized in that they recognize antigen ior C2. The recombinant antibodies are specifically chimeric antibody, humanized antibody and the single-chain Fv fragment. The chimeric antibody contains variable domains of murine immunoglobuline and the constant regions of human immunoglobuline. The humanized antibody contains the constant regions of human immunoglobuline and has been specifically modified in the murine framework regions (FRs) and within the latter, in those areas that may result in an antigenic site for cells T. The Fv fragment contains the variable domains of murine immunoglobuline. The invention also relates to the utilization of recombinant antibodies derived from murine antibody ior C5 in the diagnosis and therapy of colorectal tumors, the metastasis thereof and recurrences.
La presente invención se relaciona con la obtención de nuevos anticuerpos recombinantes a partir del anticuerpo murino ior C5 producido por el hibridoma depositado según el tratado de Budapest bajo el número ECCC 97061101. Dichos anticuerpos recombinantes se obtuvieron mediante el empleo de la tecnología del ADN recombinante, y están caracterizados por su reconocimiento al antígeno denominado ior C2. Los anticuerpos recombinantes son específicamente, el anticuerpo quimérico, el anticuerpo humanizado y el fragmento tipo Fv de cadena sencilla. El anticuerpo quimérico contiene los dominios variables de la inmunoglobulina murina y las regiones constante de la inmunoglobulina humana. El anticuerpo humanizado contiene las regiones constante de la inmunoglobulina humana y ha sido modificado específicamente en la región de los marcos (FRs) murinos y dentro de estos en aquellas zonas que pudieran resultar en un sitio antigénico par las células T. El fragmento Fv contiene los dominios variables de la inmunoglobulina murina. La presente invención además se relaciona con el uso de los anticuerpos recombinantes derivados del anticuerpo murino ior C5 para el diagnóstico y terapia de tumores colorrectales, sus metástasis y recidivas.
La présente invention concerne l'obtention de nouveaux anticorps recombinants à partir de l'anticorps murin ior C5 produit par l'hybridome qui a fait l'objet du dépôt numéro ECCC 97061101 selon le traité de Budapest. Lesdits anticorps recombinants, que l'on a obtenus par utilisation de la technologie de l'ADN recombiné, sont caractérisés en ce qu'ils reconnaissent l'antigène appelé ior C2. Ces anticorps recombinants sont notamment l'anticorps chimère, l'anticorps humanisé et le fragment du type Fv à chaîne simple. L'anticorps chimère contient les domaines variables de l'immunoglobuline murine et les régions constantes de l'immunoglobuline humaine. L'anticorps humanisé, qui contient les régions constantes de l'immunoglobuline humaine, a été modifié spécifiquement au niveau des régions charpente (framework regions) murines, et à l'intérieur de celles-ci, dans les zones susceptibles de donner lieu à un site antigénique pour les lymphocytes T. Le fragment Fv contient les domaines variables de l'immunoglobuline murine. La présente invention concerne également l'utilisation des anticorps recombinants dérivés de l'anticorps murin ior C5 pour le diagnostic et le traitement des tumeurs colorectales, de leurs métastases et de leurs récidives.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PHYSICS</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPIRITS</subject><subject>TESTING</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2001</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDB19AvxdPJ38XQNVnD0c1FwC1NwC3J093X1C1EIcnX2d_fzjPL0c1cAKXN39VPw9A9ScDbiYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXx4f4GhsZmJhamjkbGRCgBAIBEJwc</recordid><startdate>20010525</startdate><enddate>20010525</enddate><creator>DUENAS PORTO, MARTA</creator><creator>BELL GARCIA, HANSSEL</creator><creator>MATEO DE ACOSTA DEL RIO, CRISTINA MARIA</creator><creator>GAVILONDO COWLEY, JORGE VICTOR</creator><creator>MORALES MORALES, ALEJO</creator><creator>AYALA AVILA, MARTA</creator><creator>IZNAGA ESCOBAR, NORMANDO</creator><creator>RAMOS ZUZARTE, MAYRA</creator><creator>RENGIFO CALZADO, ENRIQUE</creator><creator>ROQUE NAVARRO, LOURDES TATIANA</creator><creator>PEREZ RODRIGUEZ, ROLANDO</creator><scope>EVB</scope></search><sort><creationdate>20010525</creationdate><title>ANTIBODIES AND FV FRAGMENT RECOGNIZING ANTIGEN IOR C2</title><author>DUENAS PORTO, MARTA ; BELL GARCIA, HANSSEL ; MATEO DE ACOSTA DEL RIO, CRISTINA MARIA ; GAVILONDO COWLEY, JORGE VICTOR ; MORALES MORALES, ALEJO ; AYALA AVILA, MARTA ; IZNAGA ESCOBAR, NORMANDO ; RAMOS ZUZARTE, MAYRA ; RENGIFO CALZADO, ENRIQUE ; ROQUE NAVARRO, LOURDES TATIANA ; PEREZ RODRIGUEZ, ROLANDO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO0136485A23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; spa</language><creationdate>2001</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PHYSICS</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPIRITS</topic><topic>TESTING</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>DUENAS PORTO, MARTA</creatorcontrib><creatorcontrib>BELL GARCIA, HANSSEL</creatorcontrib><creatorcontrib>MATEO DE ACOSTA DEL RIO, CRISTINA MARIA</creatorcontrib><creatorcontrib>GAVILONDO COWLEY, JORGE VICTOR</creatorcontrib><creatorcontrib>MORALES MORALES, ALEJO</creatorcontrib><creatorcontrib>AYALA AVILA, MARTA</creatorcontrib><creatorcontrib>IZNAGA ESCOBAR, NORMANDO</creatorcontrib><creatorcontrib>RAMOS ZUZARTE, MAYRA</creatorcontrib><creatorcontrib>RENGIFO CALZADO, ENRIQUE</creatorcontrib><creatorcontrib>ROQUE NAVARRO, LOURDES TATIANA</creatorcontrib><creatorcontrib>PEREZ RODRIGUEZ, ROLANDO</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>DUENAS PORTO, MARTA</au><au>BELL GARCIA, HANSSEL</au><au>MATEO DE ACOSTA DEL RIO, CRISTINA MARIA</au><au>GAVILONDO COWLEY, JORGE VICTOR</au><au>MORALES MORALES, ALEJO</au><au>AYALA AVILA, MARTA</au><au>IZNAGA ESCOBAR, NORMANDO</au><au>RAMOS ZUZARTE, MAYRA</au><au>RENGIFO CALZADO, ENRIQUE</au><au>ROQUE NAVARRO, LOURDES TATIANA</au><au>PEREZ RODRIGUEZ, ROLANDO</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ANTIBODIES AND FV FRAGMENT RECOGNIZING ANTIGEN IOR C2</title><date>2001-05-25</date><risdate>2001</risdate><abstract>The invention relates to recombinant antibodies from monoclonal antibody IOR C5 that recognizes antigen IOR C2 of colorectal cells. Said recombinant antibodies have a reduced immunogenicity due to punctual mutations in the FRs. Said antibodies are useful for the diagnosis and therapy of colorectal tumors, their metastasis and relapses.
The invention relates to the obtention of novel recombinant antibodies of novel recombinant antibodies from murine antibody ior C5 produced by the hybridome deposited under number ECCC 97061101 in accordance with the Budapest Treaty. Said recombinant antibodies were obtained using recombinant DNA technology and are characterized in that they recognize antigen ior C2. The recombinant antibodies are specifically chimeric antibody, humanized antibody and the single-chain Fv fragment. The chimeric antibody contains variable domains of murine immunoglobuline and the constant regions of human immunoglobuline. The humanized antibody contains the constant regions of human immunoglobuline and has been specifically modified in the murine framework regions (FRs) and within the latter, in those areas that may result in an antigenic site for cells T. The Fv fragment contains the variable domains of murine immunoglobuline. The invention also relates to the utilization of recombinant antibodies derived from murine antibody ior C5 in the diagnosis and therapy of colorectal tumors, the metastasis thereof and recurrences.
La presente invención se relaciona con la obtención de nuevos anticuerpos recombinantes a partir del anticuerpo murino ior C5 producido por el hibridoma depositado según el tratado de Budapest bajo el número ECCC 97061101. Dichos anticuerpos recombinantes se obtuvieron mediante el empleo de la tecnología del ADN recombinante, y están caracterizados por su reconocimiento al antígeno denominado ior C2. Los anticuerpos recombinantes son específicamente, el anticuerpo quimérico, el anticuerpo humanizado y el fragmento tipo Fv de cadena sencilla. El anticuerpo quimérico contiene los dominios variables de la inmunoglobulina murina y las regiones constante de la inmunoglobulina humana. El anticuerpo humanizado contiene las regiones constante de la inmunoglobulina humana y ha sido modificado específicamente en la región de los marcos (FRs) murinos y dentro de estos en aquellas zonas que pudieran resultar en un sitio antigénico par las células T. El fragmento Fv contiene los dominios variables de la inmunoglobulina murina. La presente invención además se relaciona con el uso de los anticuerpos recombinantes derivados del anticuerpo murino ior C5 para el diagnóstico y terapia de tumores colorrectales, sus metástasis y recidivas.
La présente invention concerne l'obtention de nouveaux anticorps recombinants à partir de l'anticorps murin ior C5 produit par l'hybridome qui a fait l'objet du dépôt numéro ECCC 97061101 selon le traité de Budapest. Lesdits anticorps recombinants, que l'on a obtenus par utilisation de la technologie de l'ADN recombiné, sont caractérisés en ce qu'ils reconnaissent l'antigène appelé ior C2. Ces anticorps recombinants sont notamment l'anticorps chimère, l'anticorps humanisé et le fragment du type Fv à chaîne simple. L'anticorps chimère contient les domaines variables de l'immunoglobuline murine et les régions constantes de l'immunoglobuline humaine. L'anticorps humanisé, qui contient les régions constantes de l'immunoglobuline humaine, a été modifié spécifiquement au niveau des régions charpente (framework regions) murines, et à l'intérieur de celles-ci, dans les zones susceptibles de donner lieu à un site antigénique pour les lymphocytes T. Le fragment Fv contient les domaines variables de l'immunoglobuline murine. La présente invention concerne également l'utilisation des anticorps recombinants dérivés de l'anticorps murin ior C5 pour le diagnostic et le traitement des tumeurs colorectales, de leurs métastases et de leurs récidives.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre ; spa |
| recordid | cdi_epo_espacenet_WO0136485A2 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS TESTING VINEGAR WINE |
| title | ANTIBODIES AND FV FRAGMENT RECOGNIZING ANTIGEN IOR C2 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T03%3A08%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=DUENAS%20PORTO,%20MARTA&rft.date=2001-05-25&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO0136485A2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |